Advertisements


Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatiti.....»»

Category: personnelSource: nytMay 16th, 2018

Glaxo, J&J"s Dual Drug HIV Regimen Succeeds in Phase III Study

Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV. GlaxoSmithKline’s GSK HIV drug subsidiary-ViiV H.....»»

Category: smallbizSource: nytAug 17th, 2018

Merck"s Keytruda Improves Survival in Head/Neck Cancer Study

Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phas.....»»

Category: worldSource: nytJul 25th, 2018

Pfizer"s Epilepsy Drug Lyrica Succeeds in Pediatric Study

Zacks.....»»

Category: topSource: redinewsMay 19th, 2018

Sanofi Has Been Stockpiling Drugs for No-Deal Brexit for Six Months

French pharmaceuticals company Sanofi SA has been making drug-shortage contingency plans for more than a year to prepare for the U.K. failing to reach a deal with the European Union on Brexit, according to a person familiar with the matter......»»

Category: smallbizSource: wsjJul 31st, 2018

Emergent BioSolutions initiates Phase 1 clinical study of anti-Zika drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 31st, 2018

Sanofi has been stockpiling drugs for no-deal Brexit: WSJ

French drugmaker Sanofi has been making drug-shortage contingency plans for more than a year to prepare for Britain and the European Union failing to reach a Brexit transition deal, the Wall Street Journal reported on Tuesday, citing a source......»»

Category: topSource: reutersJul 31st, 2018

Doctor payments increased drug prescribing by 73%, new study finds

The findings support a growing consensus that pharmaceutical companies’ sales tactics affect what drugs doctors use to treat patients......»»

Category: topSource: marketwatchJul 30th, 2018

Why the Latest Alzheimer’s Drug Study Has So Many People Confused

BAN2401, a new experimental Alzheimer’s medicine from Biogen and Eisai, raises more questions than it answers. One headline wondered .....»»

Category: europeSource: fortuneJul 30th, 2018

Sarepta stock drops after Muscular Dystrophy study halted by FDA

Sarepta Therapeutics Inc. shares fell in after-hours trading Wednesday, when the company announced a study of a potential drug for Duchenne Muscular Dystroph.....»»

Category: topSource: marketwatchJul 25th, 2018

Roche"s Tecentriq Met Primary Goal in First-Line NSCLC Study

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS). Roche H.....»»

Category: dealsSource: nytJul 19th, 2018

J&J"s (JNJ) Phase III Study for Invokana Halted Earlier

Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data. Johnson & Johnson JNJ .....»»

Category: personnelSource: nytJul 17th, 2018

Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»

Category: topSource: marketwatchJul 13th, 2018

Advaxis initiates IND with FDA to study first ADXS-HOT drug candidate for NSCLC

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018

Sanofi Genzyme "disappointed" with CADTH recommendation on Dupixent

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018

Acceleron pops, Celgene shares higher after blood-disorder drug study results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 9th, 2018

Celgene, Acceleron shares rise on blood-disorder drug study

Celgene Corp. and Acceleron Pharma Inc. sh.....»»

Category: topSource: marketwatchJul 9th, 2018

Biotech ETFs Surge on Biogen"s Positive Drug Trial Result

Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment. Biogen Inc. BIIB was a star performer in Friday’s trading session, as the stock rallied as much as 23.1% but closed a l.....»»

Category: worldSource: nytJul 9th, 2018

Drugmakers Call Experimental Alzheimer"s Drug Study Positive

Biogen and Japan’s Eisai said they had positive results from a midstage study of an experimental Alzheimer’s drug, though experts said it was too soon to say the drug marks a real advance......»»

Category: smallbizSource: wsjJul 6th, 2018

Drugmakers Call Experimental Alzheimer"s Drug Study Outcome Positive

Biogen and Japan’s Eisai sa.....»»

Category: smallbizSource: wsjJul 6th, 2018

Biogen Rallies On Positive Alzheimer"s Drug Trial

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  read more.....»»

Category: blogSource: benzingaJul 6th, 2018